Oxford University
Wellington Square
Oxford
OX1 2JD
United Kingdom
Tel: 44-1865-270000
Fax: +44-1865-270708
Website: http://www.ox.ac.uk/
213 articles with Oxford University
-
The Oxford University team behind the global COVID-19 RECOVERY study is now focusing its attention on developing a new monkeypox treatment.
-
Companies are still developing and refining treatments and preventions for COVID-19, but not all of them are approved or authorized. Here’s a look at the latest COVID-19 news.
-
Although it seems like science fiction, we may one day be able to grow replacement organs and tissues. For that and more reach news, continue reading.
-
Researchers at Oxford University have identified a gene linked to pain. The discovery opens possibilities to develop drugs or gene therapies to help treat patients who suffer from chronic pain.
-
While a handful of companies have dominated the COVID-19 vaccine market in the U.S. and Europe, a number of biotechs are continuing to develop vaccines to use as booster shots.
-
Oxford, UK-based OMass Therapeutics closed on a $100 million Series B financing round. The round was led by new investors GV (formerly Google Ventures), Northpond Ventures and Sanofi Ventures. Three existing investors also participated: Syncona, Oxford Science Enterprise and Oxford University.
-
Global health officials are monitoring COVID-19 cases with an eye to identifying the emergence of new, potentially more deadly or more infectious variants. Read on for more details.
-
Morningside Ventures launched a new biotech company called Adiso Therapeutics, and thriving startup Scenic Biotech scooped up €28 million ($31 million) in funding.
-
A study in monkeys found the virus infects the male genital tissues. For that and more COVID-19 news, continue reading.
-
Revealed in an article published in Science magazine, this new variant of HIV was discovered in individuals in the Netherlands, Belgium and Switzerland.
-
As the spread of the Omicron variant of COVID-19 picks up speed, vaccine makers are rushing to test their shots against the new mutation, with mixed results.
-
Two years into the COVID-19 pandemic, countries are reporting the fourth wave of rising cases, driven mainly by the Delta variant, although Omicron has everybody concerned. Here’s a look.
-
numares and Oxford University sign exclusive license agreement for novel multi-marker diagnostics in multiple sclerosis
10/28/2021
Leading NMR diagnostics company numares AG announced that the company signed an exclusive licence agreement with Oxford University Innovation.
-
It proved itself superior to AZD1222 (ChAdOx1-S), the vaccine by Astrazeneca-Oxford, in terms of geometric mean titer for neutralization antibodies.
-
Research on the ever-evolving SARS-CoV-2 virus continues as scientists scramble to make sense of it and find cures. Here's a look.
-
With Pfizer expected to submit its COVID-19 vaccine data for children five to 11 years to regulators, a study showed just how damaging the pandemic has been to life expectancy. Here’s a look.
-
SENS Research Foundation released findings that confirmed the charges of inappropriate behavior raised by two former female employees against Aubrey de Grey.
-
Scientists from the U.K. conducted a massive study on the link between vaccinations and dropping platelet counts and found that the problem lies more on the virus itself than on the medications.
-
Scientists from Oxford University may have found the key to treating endometriosis, a disease that affects around 176 million women worldwide.
-
SIGA Announces Collaboration with Oxford University to Support Expanded Access Protocol for Use of TPOXX® (Tecovirimat) To Treat Monkeypox in Central African Republic
7/29/2021
SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on the health security market, announced that it has entered into a collaboration with Oxford University in the United Kingdom to provide TPOXX® under an expanded access protocol to treat individuals affected by monkeypox in the Central African Republic.